Immunovant, Inc. (IMVT)

NASDAQ: IMVT · IEX Real-Time Price · USD
-0.02 (-0.10%)
Jun 2, 2023, 4:00 PM EDT - Market closed

Total Valuation

Immunovant has a market cap or net worth of $2.69 billion. The enterprise value is $2.32 billion.

Market Cap 2.69B
Enterprise Value 2.32B

Important Dates

The last earnings date was Monday, May 22, 2023, before market open.

Earnings Date May 22, 2023
Ex-Dividend Date n/a

Share Statistics

Immunovant has 130.41 million shares outstanding. The number of shares has increased by 12.21% in one year.

Shares Outstanding 130.41M
Shares Change (YoY) +12.21%
Shares Change (QoQ) +1.35%
Owned by Insiders (%) 58.66%
Owned by Institutions (%) 43.88%
Float 48.42M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS 3,036.42
PB Ratio 7.43
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 9.34, with a Debt / Equity ratio of 0.00.

Current Ratio 9.34
Quick Ratio 8.71
Debt / Equity 0.00
Debt / EBITDA n/a
Debt / FCF n/a

Financial Efficiency

Return on equity (ROE) is -52.40%.

Return on Equity (ROE) -52.40%
Return on Assets (ROA) -48.30%
Return on Capital (ROIC) n/a
Revenue Per Employee n/a
Profits Per Employee -$1.29M
Employee Count 164
Asset Turnover n/a
Inventory Turnover n/a


In the past 12 months, Immunovant has paid $9,000 in taxes.

Income Tax 9,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +403.16% in the last 52 weeks. The beta is 1.02, so Immunovant's price volatility has been similar to the market average.

Beta (1Y) 1.02
52-Week Price Change +403.16%
50-Day Moving Average 17.46
200-Day Moving Average 13.96
Average Volume (30 Days) 1,012,528

Short Selling Information

The latest short interest is 4.31 million, so 3.30% of the outstanding shares have been sold short.

Short Interest 4.31M
Short Previous Month 4.53M
Short % of Shares Out 3.30%
Short % of Float 8.89%
Short Ratio (days to cover) 4.97

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -218.53M
Pretax Income -210.95M
Net Income -210.96M
EBITDA -209.63M
EBIT -210.95M
Earnings Per Share (EPS) -$1.71
Full Income Statement

Balance Sheet

The company has $376.53 million in cash and $1.22 million in debt, giving a net cash position of $375.31 million or $2.88 per share.

Cash & Cash Equivalents 376.53M
Total Debt 1.22M
Net Cash 375.31M
Net Cash Per Share $2.88
Equity / Book Value 362.49M
Book Value Per Share 2.78
Working Capital 361.04M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$188.19 million and capital expenditures -$197,000, giving a free cash flow of -$188.39 million.

Operating Cash Flow -188.19M
Capital Expenditures -197,000
Free Cash Flow -188.39M
FCF Per Share -$1.53
Full Cash Flow Statement


Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Immunovant does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Earnings Yield -7.83%
FCF Yield -6.99%
Dividend Growth (YoY) n/a
Payout Ratio n/a
Buyback Yield -12.21%
Shareholder Yield -12.21%
Dividend Details

Analyst Forecast

The average price target for Immunovant is $23.38, which is 13.17% higher than the current price. The consensus rating is "Strong Buy".

Price Target $23.38
Price Target Difference 13.17%
Analyst Consensus Strong Buy
Analyst Count 13
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a